QURE
uniQure N.V.Company Information
- Company Name
- uniQure N.V.
- CIK
- CIK0001590560
- Category
- Large accelerated filer
- Ticker: Exchange
- QURE: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- QURE
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-07-02
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 704,718
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 65,089,021
- Shares outstanding
- 62,742,847
- Ownership
- 103.74%
Earnings Market Reaction
- Filing date
- 2026-05-05
- Price on filing date
- —
- 1-month reaction
- 34.83%
- 3-month reaction
- 84.17%
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 140 | 80 | 597 | 254 | 217 | 159 | 252 | 288 | 243 | 241 | 229 | 514 | ||||||
| Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current | 447 | 542 | 97 | 123 | 192 | 209 | 184 | 237 | 313 | 377 | 429 | 115 | ||||||
| Inventory Net | - | - | - | - | - | - | - | - | 8 | 12 | 16 | 10 | ||||||
| Accounts Receivable Net Current | 4 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense Current | 17 | 21 | 10 | 19 | 13 | 9 | 19 | 18 | 19 | 15 | 15 | 12 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | 38 | - | - | - | - | ||||||
| Assets Current | 616 | 656 | 716 | 409 | 435 | 390 | 464 | 592 | 596 | 652 | 694 | 757 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | 12 | 14 | 15 | 17 | 18 | 20 | 26 | 26 | 45 | 47 | 46 | 49 | ||||||
| Other Investments | - | - | 30 | 30 | 28 | 27 | 28 | - | - | 2 | - | - | ||||||
| Other Long Term Investments | 30 | 30 | - | - | - | 27 | - | - | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 12 | 13 | 13 | 14 | 13 | 14 | 15 | 15 | 28 | 29 | 30 | 31 | ||||||
| Intangible Assets Net Excluding Goodwill | 70 | 73 | 74 | 76 | 72 | 71 | 77 | 59 | 59 | 60 | 58 | 60 | ||||||
| Goodwill | 25 | 25 | 25 | 25 | 23 | 22 | 24 | 23 | 26 | 26 | 25 | 26 | ||||||
| Deferred Income Tax Assets Net | 8 | 9 | 9 | 9 | 9 | 10 | 11 | 11 | 12 | 12 | 12 | 14 | ||||||
| Other Assets Noncurrent | 6 | 6 | 5 | 5 | 5 | 1 | 1 | 5 | 5 | 3 | 6 | 6 | ||||||
| Assets Noncurrent | 163 | 169 | 172 | 176 | 170 | 166 | 182 | 139 | 174 | 180 | 178 | 186 | ||||||
| Assets | 779 | 825 | 888 | 585 | 605 | 557 | 646 | 731 | 770 | 832 | 872 | 943 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 5 | 6 | 6 | 5 | 7 | 5 | 4 | 5 | 7 | 6 | 9 | ||||||
| Accrued Liabilities Current | 43 | 41 | 52 | 31 | 27 | 29 | 32 | 26 | 23 | 31 | 28 | 24 | ||||||
| Accrued Income Taxes Current | - | - | 8 | - | - | - | - | - | - | - | - | - | ||||||
| Business Combination Contingent Consideration Liability Current | - | 0 | - | - | - | 0 | 29 | 28 | 28 | 28 | 27 | 28 | ||||||
| Operating Lease Liability Current | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 8 | 8 | 8 | 8 | ||||||
| Liabilities Current | 59 | 63 | 101 | 41 | 36 | 40 | 71 | 80 | 63 | 74 | 69 | 68 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | 18 | - | - | - | - | ||||||
| Long Term Debt Noncurrent | 50 | 50 | 52 | 52 | 52 | 51 | 51 | 103 | 102 | 102 | 101 | 101 | ||||||
| Operating Lease Liability Noncurrent | 10 | 10 | 10 | 11 | 11 | 11 | 12 | 12 | 27 | 28 | 29 | 30 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 17 | 19 | 18 | 16 | 13 | 11 | 12 | 12 | 15 | 15 | 14 | 10 | ||||||
| Deferred Income Tax Liabilities Net | 8 | 8 | 8 | 8 | 7 | 7 | 8 | 7 | 7 | 8 | 5 | 7 | ||||||
| Other Liabilities Noncurrent | 3 | 4 | 6 | 6 | 6 | 8 | 9 | 3 | 3 | 4 | 1 | 1 | ||||||
| Liabilities Noncurrent | 570 | 563 | 559 | 548 | 535 | 523 | 519 | 553 | 560 | 550 | 534 | 521 | ||||||
| Liabilities | 629 | 626 | 660 | 589 | 572 | 563 | 590 | 634 | 623 | 624 | 603 | 589 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Additional Paid In Capital | 1,588 | 1,582 | 1,576 | 1,263 | 1,258 | 1,173 | 1,166 | 1,163 | 1,156 | 1,149 | 1,142 | 1,131 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -60 | -58 | -59 | -59 | -54 | -53 | -57 | -56 | -56 | -54 | -59 | -52 | ||||||
| Retained Earnings Accumulated Deficit | -1,382 | -1,329 | -1,292 | -1,211 | -1,174 | -1,130 | -1,057 | -1,012 | -956 | -890 | -817 | -728 | ||||||
| Stockholders Equity | 149 | 199 | 229 | -4 | 34 | -7 | 56 | 97 | 147 | 208 | 269 | 353 | ||||||
| Liabilities And Stockholders Equity | 779 | 825 | 888 | 585 | 605 | 557 | 646 | 731 | 770 | 832 | 872 | 943 | ||||||
| In Process Research And Development | - | - | 0 | 5 | 58 | - | 2 | -0 | 58 | - | -2 | 0 | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | - | - | 44 | 41 | 36 | - | 31 | 28 | 58 | - | 52 | 49 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | ||||||
| Common Stock Shares Authorized | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | ||||||
| Common Stock Shares Issued | 63 | 62 | 62 | 55 | 55 | 49 | 49 | 49 | 48 | 48 | 48 | 48 | ||||||
| Shares Outstanding | 63 | 62 | 62 | 55 | 55 | 49 | 49 | 49 | 48 | 48 | 48 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialuniQure N.V. (QURE) — SEC Financial Statements & Analysis
uniQure N.V. (QURE) is a pharmaceutical preparations company. uniQure N.V. trades on Nasdaq as: QURE. uniQure N.V. (QURE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-05. Based on that filing, uniQure N.V. carries a market cap of $1.03B, a P/E ratio of -4.91x, a P/B ratio of 6.87x, a P/S ratio of 56.70x, an enterprise value of $934.25M, and an EV/EBITDA multiple of -5.23x. On profitability, it posts a gross margin of 109.44%, an operating margin of -1059.74%, a net margin of -1154.42%, a Return on Equity (ROE) of -228.24%, a Return on Assets (ROA) of -30.18%, and a Return on Invested Capital (ROIC) of -693.38%. Per share, it reports EPS of $-3.33, diluted EPS of $-3.33, free cash flow per share of $-2.75, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -10.44% year-over-year, net income growth of -4.00% year-over-year, and EPS growth of -18.74% year-over-year. On the balance sheet, it maintains a current ratio of 10.40x, a quick ratio of 10.12x, working capital of $556.55M, a debt-to-equity ratio of 4.21x, a debt ratio of 0.81, an interest coverage ratio of -3.15x, free cash flow of $-172.69M (TTM), and net debt of $-91.59M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.03B
- P/E TTM
- -4.91x
- EPS TTM
- $-3.33
- P/B TTM
- 6.87x
- ROE TTM
- -228.24%
- ROA TTM
- -30.18%
- Debt To Equity
- 4.21x
- Free Cash Flow TTM
- $-172.69M
- Net Revenue TTM Growth 1Y
- -10.44%
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is uniQure N.V. in?
uniQure N.V. (QURE) operates in the Pharmaceutical Preparations industry.
What exchange does QURE trade on?
uniQure N.V. (QURE) trades on the Nasdaq.
When was uniQure N.V. (QURE)'s most recent SEC filing?
uniQure N.V. (QURE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-05.
What is QURE's market cap?
uniQure N.V. (QURE) has a market capitalization of $1.03B as of 2026-03-31.
What is QURE's EPS (earnings per share)?
uniQure N.V. (QURE)'s trailing twelve month EPS is $-3.33 as of 2026-03-31.
What is QURE's ROE (return on equity)?
uniQure N.V. (QURE)'s trailing twelve month Return on Equity (ROE) is -228.24% as of 2026-03-31.
What is QURE's ROA (return on assets)?
uniQure N.V. (QURE)'s trailing twelve month Return on Assets (ROA) is -30.18% as of 2026-03-31.
What is QURE's ROIC (return on invested capital)?
uniQure N.V. (QURE)'s trailing twelve month Return on Invested Capital (ROIC) is -693.38% as of 2025-12-31.
What is QURE's EV/EBITDA?
uniQure N.V. (QURE)'s trailing twelve month EV/EBITDA is -5.23x as of 2026-03-31.